In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Satsuma Pharmaceuticals (STSA), with a price target of $15.00. The company’s shares closed last Wednesday at $5.20, close to its 52-week low of $3.50.
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 7.4% and a 47.8% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Satsuma Pharmaceuticals is a Moderate Buy with an average price target of $8.38.
Based on Satsuma Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $12.48 million. In comparison, last year the company had a GAAP net loss of $10.81 million.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STSA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.